
https://www.science.org/content/blog-post/industrial-diels-alder-revisited-detail
# The Industrial Diels–Alder, Revisited in Detail (February 2013)

## 1. SUMMARY
The article revisits the industrial use of the Diels–Alder reaction in pharmaceutical manufacturing and drug discovery. The author cites multiple surveys indicating that despite being a fundamental organic reaction, the Diels–Alder reaction falls into the "miscellaneous" category, accounting for only 5–11% of C–C bond-forming reactions under Good Manufacturing Practice conditions. The reaction represents only about 1.8% of the total reaction repertoire used by medicinal chemists pursuing drug candidates, with palladium-catalyzed reactions dominating at roughly 60% of occurrences. 

Examination of the top 200 pharmaceutical products by US retail sales in 2010 revealed only three drugs produced industrially using the Diels–Alder reaction: Buprenorphine, Calcitriol, and its precursor Calciferol. From 2002 to 2010, among 174 new chemical entities introduced to the market, only two examples utilized Diels–Alder in manufacturing: Varenicline (Pfizer, 2006) and Peramivir (Shionogi, 2010). The author notes its wider application in fragrance chemistry but concludes the reaction appears underutilized given its synthetic power, despite practical challenges like potential polymerization of starting materials.

## 2. HISTORY
The 2024 analysis by Forni et al. in *Chemistry – A European Journal* comprehensively addresses this gap, examining the Diels–Alder reaction's role in manufacturing FDA-approved drugs from 2011–2023. Their systematic review identified 41 active pharmaceutical ingredients manufactured using this reaction, finding only 13 explicitly stated in regulatory documents to undergo Diels–Alder cycloaddition, while 20 involved Diels–Alder chemistry in fine chemical API production described in patents or scientific literature. Eight more had plausible but unconfirmed Diels–Alder involvement.

Several notable drugs entered the market or expanded manufacturing using Diels–Alder chemistry during this period. Cobicistat, a pharmacoenhancer for HIV therapies (approved 2012, used with atazanavir; 2014 with darunavir; 2015 as Genvoya, 2016 as Odefsey, 2016 as Descovy), is prepared through a Diels–Alder intermediate. Belzutifan, an HIF-2α inhibitor for von Hippel-Lindau disease (approved 2021), utilizes Diels–Alder chemistry in its industrial synthesis. OrLISTAT, produced by North China Pharmaceutical Group, reportedly involves Diels–Alder intermediates, as do selinexor and pembrolizumab, though the latter is a monoclonal antibody where Diels–Alder chemistry might have been used in the development process or in excipients. Other drugs mentioned by Forni with Diels–Alder components or intermediates include butamisole, carbetocin, tilmicosin, sugammadex, and glecaprevir/pibrentasvir.

Efforts to address Diels–Alder limitations continued through 2023, with research on asymmetric catalysts and milder conditions. However, the core infrastructure of pharmaceutical manufacturing largely maintained established reaction protocols, and Diels–Alder remained secondary to cross-coupling reactions in industrial drug production.

## 3. PREDICTIONS
• **Implicit prediction**: The author's comment that Diels–Alder "would seem to have more use than it gets" suggests an expectation that industrial adoption would increase.
  - **Outcome**: The Forni 2024 study confirmed continued limited but specific use, with 41 APIs (2011–2023) involving Diels–Alder chemistry, showing the technique maintained a specialized niche rather than widespread adoption.

• **Implicit prediction**: The article implies that the reaction's potential problems (particularly polymerization risks) contribute to its industrial scarcity.
  - **Outcome**: Research into asymmetric catalysts and optimized conditions through 2023 suggests these technical challenges persisted, requiring specialized expertise for successful scale-up.

• **No explicit predictions were made**: The article primarily documented the historical scarcity rather than forecasting future developments.

## 4. INTEREST
Rating: **6/10**
The article addresses an important but narrow technical gap in pharmaceutical manufacturing with documented evidence, though limited scope beyond industrial chemistry applications.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20130228-industrial-diels-alder-revisited-detail.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_